Additionally, increasing use of advances such as prostate-specific membrane antigen based PET or CT imaging and 3 T MRI in the diagnosis of prostate cancer are also likely to have influenced the overall economic burden of disease. This evidence concerns the gene FOLH1 and prostate cancer.